There is a small cafe in the exhibition hall, surrounded by a group of bodyguards in black. Li Rui, Ye Bingling and Feng Xinqiao were sitting opposite each other.

After both parties introduced themselves, Ye Bingling nervously didn't know where to put her hands.

Suddenly, a hand reached out and grabbed her somewhat cold palm.

Ye Bingling trembled all over and wanted to shake him off, but he felt extremely warm and safe.

Anyway, it didn’t matter that they had kissed each other and held hands. An idea that had never occurred to her before flashed through Ye Bingling’s mind, and she let Li Rui hold her hand.

Holding Ye Bingling's hand under the table, Li Rui was in a good mood, so he cleared his throat and said: Mr. Feng, do you need me to elaborate?

Please. Feng Xinqiao said with some excitement.

Li Rui said calmly: Mr. Feng, has he ever heard of Gleevec?

Feng Xinqiao nodded and said: Gleevec is a specific targeted drug used to treat bcr-abl mutated chronic leukemia. I didn't know it before, but since Xiaoxian became ill, I have done a lot of research on medical biotechnology.

Li Ruidao: That's right. Gleevec is the first truly specific targeted drug. It is a chemotherapy drug with strong specificity for cancer cells. It only kills cancer cells and does not affect normal cells. The emergence of Gleevec,

The five-year survival rate of patients has increased from 30% to 89%! Now, many similar new drugs are being studied, and some of them have entered the clinical trial stage.

Feng Xinqiao's face became a little rosy: I have also looked for similar new drugs, but there is currently no one for Xiaoxian's disease. Do you know?

Li Ruidao: In 1992, some scientists discovered that T cells contain an important immunosuppressive receptor molecule called PD-1. On this basis, they prepared monoclonal antibodies that specifically block the effect of PD-1 and carried out clinical treatment of tumor patients.

Treatment trial. After more than ten years of research, a Chinese pharmaceutical company invented the anti-PD-L1 therapy drug durvalumab, also called imfinzi, three years ago.

Feng Xinqiao's whole body tensed up, he was very nervous, and he stuttered when he spoke: Do you think this medicine can cure Xiaoxian's disease?

Li Ruidao: This drug is currently in phase III pacific clinical trials. The use of Infinifer immunotherapy after concurrent radiotherapy and chemotherapy can reduce the risk of death by nearly 32% in patients with stage III unresectable small cell cancer, and the median disease progression-free survival period is

The duration is 16.8 months, and the 3-year overall survival rate is as high as 57%. This is the world's first PD-L1 immunosuppressant for the treatment of stage III lung cancer.

How can I use this medicine? Feng Xinqiao asked quickly.

Li Ruidao: This drug is still in clinical trials. Under normal circumstances, it will take three to five years to be approved for marketing, but Mr. Feng should have a way to get it.

As he spoke, Li Rui stepped forward and told Feng Xinqiao in a low voice the company and laboratory that developed Infinifer.

After Feng Xinqiao listened, his face was filled with uncontrollable joy, because what he heard from Li Rui was a famous name of a pharmaceutical company.

Since it is a new drug developed by that company, it should be effective, right?

Feng Xinqiao was so excited that he couldn't stay still for a second. He took out a business card and handed it to Li Rui solemnly: Thank you for providing me with the information. No matter what the outcome is, I owe you a favor. I am now anxious to tell the Magnesium authorities

Contact me, I won’t talk to you any more.

Wish you good luck. Li Rui didn't say anything more.

Feng Xinqiao hurried away with a group of bodyguards.

It wasn't until they were far away that Ye Bingling breathed a sigh of relief and said with lingering fear: Li Rui, what did you just say to him?

I told him that Infinifer is a new drug developed by AstraZeneca. With Mr. Feng’s financial resources and connections, it should be no problem to get some drugs from AstraZeneca’s laboratory, Li Ruidao said.

How do you know that the medicine developed by AstraZeneca's laboratory can treat Mr. Feng's wife? Ye Bingling looked confused.

Li Rui smiled.

How did he know?

Of course I knew this from reading reports in my previous life.

In his previous life, Wei Xiaoxian passed away in early 2011. Feng Xinqiao suffered a severe blow and was unable to recover. His panic disorder was so severe that it affected his normal life. Every time he had an attack, he felt like he was dead.

During the same period, several pillar industries of Dasheng Group were encircled by competitors and fell into trouble.

Under internal and external difficulties, Feng Xinqiao sold off his properties one after another, and Dasheng Group delisted from Nasdaq privatization and transformed into a private investment company.

Feng Xinqiao then fled to Lion City and spent billions to fund biotechnology research, including the development of new anti-cancer drugs.

In 2015, Infinifer was approved by the FDA for marketing in China. In 2019, Infinifer was approved for marketing in China, saving the lives of hundreds of thousands of patients with advanced lung cancer.

Many people are daydreaming that if Yingfeifan could go public earlier, it would save his wife's life, and the Dasheng Group would not be transformed. It is not certain who will rule the country's Internet arena.

Li Rui helped Feng Xinqiao not only because he was his idol in his previous life, but also because he hoped that Feng Xinqiao could stay in the world to muddy the waters and delay the rise of Ahri and Penguin.

Moreover, Li Rui also took a fancy to the industries and talents of Dasheng Group.

Dasheng Games is currently one of the top three game companies in the country, and Dasheng Literature is the number one online literature company in the country. These are important components of the great entertainment industry chain that Li Rui dreams of.

If these two industries can be brought under the banner, more than half of Li Rui's grand entertainment dream will be realized.

As for talents, Dasheng Group is full of talents.

Many people currently working in the Monkey King Group will become leaders in the Internet world in the future. For example, Zhang Jiayong, the current CFO of the Monkey King Group, will become Jack's successor to control Ahri in ten years.

In the previous life, the Monkey King Group was beyond the pace of the times and stumbled. Later, it staggered and could no longer keep up.

In this life, Li Rui hopes to replace the Monkey King Group to make up for those regrets.

Ye Bingling was stunned by Li Rui's mysterious appearance.

She was really scared today.

In the past, whether Li Rui was speculating in stocks, driving a Bentley, or even talking about setting up a listed company, Ye Bingling didn't say anything, but she admired him in her heart.

But deep down in her bones, she has always hidden a sense of pride and is unwilling to admit that she is weaker than Li Rui.

Until just now, when Li Rui was talking to Feng Xinqiao, she didn't dare to express her anger, and finally realized the gap between the two parties.

This guy is obviously so powerful, why did he come to my company as a small employee with a monthly salary of 3,700?

Ye Bingling felt that Li Rui must have other intentions.
Chapter completed!